ZURA
HEALTHCAREZura Bio Ltd - Class A
Live · NASDAQ · May 9, Close
What's Moving ZURA Today?
No stock-specific AI insight has been generated for ZURA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.89
Fundamentals
Trading
ZURA News
21 articles- Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate UpdatesYahoo Finance·May 7, 2026
- Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 4, 2026
- One Zura Bio Insider Raised Their Stake In The Previous YearYahoo Finance·Apr 23, 2026
- JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public OfferingBenzinga·Apr 20, 2026
- Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate UpdatesYahoo Finance·Mar 19, 2026
- UniFirst, Elastic NV, and More Stocks See Action From Activist InvestorsYahoo Finance·Mar 7, 2026
- Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World CongressYahoo Finance·Mar 5, 2026
- Zura Bio to Participate in Upcoming Investor ConferencesYahoo Finance·Mar 2, 2026
- Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesYahoo Finance·Feb 27, 2026
- Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 MillionMotley Fool·Feb 25, 2026
- This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer EmergesMotley Fool·Feb 25, 2026
- Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 CatalystMotley Fool·Feb 25, 2026
- Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsYahoo Finance·Feb 25, 2026
- Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsYahoo Finance·Feb 24, 2026
- Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of DirectorsYahoo Finance·Feb 23, 2026
- Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026Marketbeat·Feb 16, 2026
- Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech SummitYahoo Finance·Feb 4, 2026
- Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive OfficerYahoo Finance·Jan 21, 2026
- Zura Bio Reports Business Updates and Outlook for 2026Yahoo Finance·Jan 12, 2026
- December 2025's Top Penny Stocks With Promising PotentialYahoo Finance·Dec 15, 2025
- Bullish Outlook on Zura Bio Limited (ZURA) Amid Tibulizumab Phase 2 Clinical Trial ProgressYahoo Finance·Nov 29, 2025
All 21 articles loaded
Price Data
52-Week Range
$4.89
Fundamentals
Trading
About Zura Bio Ltd - Class A
Zura Bio Limited (Ticker: ZURA) is a forward-thinking biotechnology company focused on developing transformative therapies for autoimmune disorders and rare diseases. The company is poised for growth with a robust pipeline of innovative drug candidates, underscored by its commitment to rigorous clinical trials and cutting-edge research methodologies. Guided by an experienced management team and bolstered by strategic partnerships, Zura Bio is strategically positioned within the biopharmaceutical sector, presenting significant opportunities for institutional investors seeking exposure to advanced therapeutic solutions in an evolving marketplace.